A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Titel:
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Auteur:
Park, S. Lee, M.-H. Seong, M. Kim, S.T. Kang, J.-H. Cho, B.C. Lee, K.H. Cho, E.K. Sun, J.-M. Lee, S.-H. Ahn, J.S. Park, K. Ahn, M.-J.